MEDICO vs PPLPHARMA: Stock Comparison

MEDICO REMEDIES vs PIRAMAL PHARMAUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

PIRAMAL PHARMA is the larger company by market capitalisation. MEDICO REMEDIES shows a higher ROE, faster revenue growth and a higher ROCE, while PIRAMAL PHARMA shows a lower P/E and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

MEDICO leads 5; PPLPHARMA leads 7 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

MEDICOPPLPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹329 Cr
₹28,438 Cr
P/E RatioPPLPHARMA has the lower reading
26.66x
0x
P/B RatioPPLPHARMA has the lower reading
4.86x
3.49x
EPSPPLPHARMA has the higher reading
₹0.3
₹0.85
Book ValueContext only
₹9.1
₹61.31
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
PPLPHARMA is the larger company
₹28,438 Cr vs ₹329 Cr
P/E Ratio
PPLPHARMA has a lower P/E
0x vs 26.66x
P/B Ratio
PPLPHARMA has a lower P/B
3.49x vs 4.86x
EPS
PPLPHARMA has higher earnings per share
₹0.85 vs ₹0.3
Revenue Growth (TTM YoY)
MEDICO has faster revenue growth
37.5% vs -0.1%
EPS Growth (TTM YoY)
MEDICO has faster EPS growth
36.5% vs 0%
Qtr Sales Growth
PPLPHARMA has stronger quarterly sales growth
-50.44% vs -66.37%
Qtr Profit Growth
PPLPHARMA has stronger quarterly profit growth
263.54% vs -80.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMEDICOPPLPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMEDICOPPLPHARMA
Live Price₹39.87₹214.22
Day Change0.94%-0.13%
Volume52,93226.18 L
52-Week High₹56.88₹220.36
52-Week Low₹30.22₹132.3
Distance from 52W High-29.91%-2.79%

Valuation

MetricMEDICOPPLPHARMA
Market Cap₹329 Cr₹28,438 Cr
P/E Ratio26.66x0x
P/B Ratio4.86x3.49x
EPS₹0.3₹0.85
Book Value₹9.1₹61.31
Dividend Yield0%0%

Growth

MetricMEDICOPPLPHARMA
Revenue Growth (TTM YoY)37.5%-0.1%
EPS Growth (TTM YoY)36.5%0%
Qtr Sales Growth-66.37%-50.44%
Qtr Profit Growth-80.8%263.54%

Profitability & Leverage

MetricMEDICOPPLPHARMA
ROE17.38%8.6%
ROCE15.61%9.1%
Net Margin6.36%-3.68%
Operating Margin9.63%20.01%
Debt to Equity0.25x0.09x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricMEDICOPPLPHARMA
Promoter Holding61.38%34.8% 0.06 pp
FII Holding0.08% 0.05 pp12.52% 17.66 pp
DII Holding0%14.57% 1.04 pp
Public Holding38.54% 0.05 pp37.63% 18.62 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MEDICO REMEDIES and PIRAMAL PHARMA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.